Stock AnalizGuardant Health, Inc. GH
Medical Specialities · IPO 2018 · data as of November 13, 2026
Guardant Health, Inc. (GH) is a healthcare company listed in the US with a market value of about $20.5B. In the twelve months to September 30, 2026 it had revenue of $1.3B and net income of -$485M, a net margin of -37.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 28% a year, a 5-year average ROIC of -26%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $982M | $739M | $564M | $450M | $374M | $287M | $214M | $91M | $50M | $25M |
| Net income | -$485M | -$416M | -$436M | -$479M | -$655M | -$385M | -$254M | -$76M | -$85M | -$83M | -$46M |
| Free cash flow | -$232M | -$233M | -$275M | -$345M | -$387M | -$284M | -$140M | -$66M | -$92M | -$79M | -$38M |
| EPS (diluted) | $-3.68 | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 | $-0.84 | $-2.80 | $-7.07 | $-3.53 |
| Net margin | -37.9% | -42.4% | -59.1% | -85.0% | -145.6% | -103.0% | -88.5% | -35.3% | -93.8% | -167.0% | -182.7% |
| ROIC | — | -27.1% | -29.3% | -29.5% | -30.1% | -16.1% | -9.3% | -9.6% | -14.5% | -19.6% | -43.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 25 analysts is $200.76, 32% above the current price; targets range from $105.00 to $240.00; the consensus rating is “Strong buy”; expected EPS is $-1.45 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Guardant Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Guardant Health pay a dividend?
Not currently.
Is Guardant Health a good stock to buy?
We do not give buy or sell advice. Guardant Health scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.